Bolus Injectors Market

Transcription

1 Sample Pages Bolus Injectors Market Copyright 2012 Banyan Wharf Consultants Ltd. Page 1

2 This page is intentionally left blank Copyright 2013 Roots Analysis Private Ltd. All rights reserved. No part of this report should be copied or reproduced in any format without the prior consent of Roots Analysis. The Company accepts no liability, whatsoever, for the actions of third party in this respect.

3 3.7. BOLUS INJECTORS UNDER DEVELOPMENT Bolus injectors are special types of patch based injectors which can deliver large, standardized volume of dose into the subcutaneous layer over a defined period of time. Table 3.3 highlights the various bolus injectors, including the mode of operation, which are currently under development. Table 3.3 Bolus Injectors Under Development S. No. Product Name Company Volume of Injector Mode of Operation Use 1 MyDose Roche Diagnostics Upto 15 ml Electronic Disposable 2 Precision Therapy Platform Unilife Upto 30 ml Electronic Disposable 3 Flex Therapy Unilife Upto 30 ml Electronic Disposable 4 Smart Dose Electronic Patch Injector West Pharmaceutical 2.5 ml ml Electronic Disposable 5 Microinfusor BD Upto 15 ml Mechanical Disposable 6 NuPrivo platform Ratio Inc. Upto 5 ml Hydrogel Disposable Complete list of bolus injectors provided in the full report Report Page BOLUS INJECTORS: DISTRIBUTION BY MODE OF OPERATION As shown in Figure 3.2 and Table 11.2, a significant proportion (67%) of the bolus injectors being developed is electronic. Many of these injectors have an audio / visual panel which communicate the drug delivery progress to the user. Other modes of operation include mechanical, hydrogel and hydraulic. Figure 3.2 Bolus Injectors: Distribution by Modes of Operation 17% 8% 8% 67% Electronic Mechanical Hydrogel Hydraulic All bolus injectors are being designed to deliver drugs which are required to be delivered in high volume (more than 1 ml per dose). Figure 3.3 and Table 11.3 highlight the distribution of these injectors based on existing advertised capacity. Unilife s Precision and Flex Therapy Platforms offer the biggest volume delivery potential (30 ml). Copyright 2013 Roots Analysis Private Limited Page 3

4 BIOLOGICS MARKET FORECAST, During , biologics market is expected to grow at a CAGR of 6.0%, generating sales of USD 215 billion by According to our estimates, biologics will represent about 23.3% of the total drugs market in 2018 as compared to 20.3% in Pharmaceutical market will demonstrate low sales growth during the same time period (CAGR of 2.9%), primarily due to the patent cliff facing the industry. The overall drugs market is projected to grow at CAGR of 3.6% and is likely to register sales of USD 921 billion in Figure 4.2 and Table 11.6 present the market forecast for period Report Page 43 Figure 4.2 Drugs Market Forecast, Short - Mid Term Forecast ( ) - Split by Biologics and Pharmaceuticals (USD BN) Pharmaceuticals Biologics E 2014 E 2015 E 2016 E 2017 E 2018 E Longer term, we anticipate the total drugs market to grow to USD 1,138 billion by 2023, representing a CAGR of 4.3% between 2018 and Biologics, in particular, are expected to contribute about 22% of this market. Figure 4.3 and Table 11.7 present our long term forecast. Copyright 2013 Roots Analysis Private Limited Page 4

5 BIOLOGICS UNDER CONSIDERATION FOR BOLUS INJECTORS For the purposes of our report, we studied close to 900 biologics which are either currently marketed or under various phases of clinical development. We classified these biologics in 15 disease areas and shortlisted 253 drug-disease combinations which are the likely target for delivery via bolus injectors. Table 4.1 provides details of these 253 drug-disease combinations, respective indications, phase of development and the expected launch year. Molecules highlighted in Orange are already marketed for a particular indication. The expected year of launch in this table represents the likely launch of the drug in the market as intravenous infusion formulation. We expect the drugs to take another two years before they can be formulated for subcutaneous delivery via bolus injectors. Table 4.1 Biologics Under Consideration for Bolus Injectors Report Page 45 S.No. Molecule Disease Area Sponsor Indication Phase of Development Expected Launch Year 1 2 Alemtuzumab (Lemtrada) Belimumab subcutaneous (Benlysta)* Autoimmune Genzyme Relapsing-remitting multiple sclerosis Marketed - Autoimmune GSK SLE III BI Autoimmune Boehringer Ingelheim Rheumatoid arthritis III BIIB033 Autoimmune Biogen Idec Multiple sclerosis II Daclizumab Autoimmune Abbvie, Biogen Idec Multiple sclerosis (relapsing forms) III Epratuzumab Autoimmune Immunomedics, UCB Systemic lupus erythematosus III Interferon beta- 1b(NU-100) Autoimmune Nuron Biotech Multiple sclerosis III Natalizumab (Tysabri) Autoimmune Biogen Idec Secondary-progressive multiple sclerosis III Ofatumumab (subcutaneous)* Autoimmune GSK Multiple sclerosis II 2018 Rheumatoid arthritis II Orencia Autoimmune BMS Rheumatoid arthritis Marketed - Early rheumatoid arthritis III Otelixizumab Autoimmune GSK Rheumatoid arthritis I PDA-001 Autoimmune Celgene Rheumatoid arthritis II PF Autoimmune Pfizer Rheumatoid arthritis I/II Remicade infliximab Autoimmune Janssen Biotech Rheumatoid arthritis Marketed - 15 Rituxan Autoimmune Genentech Rheumatoid arthritis Marketed - Continued on next few pages in the full report to cover 15 disease areas (253 drug-disease combinations) Note: Drugs highlighted in Orange are already marketed for a particular indication * The marked drugs are under development for the corresponding condition as subcutaneous formulation. Copyright 2013 Roots Analysis Private Limited Page 5

6 6.3. OVERALL BOLUS INJECTORS MARKET, In the base scenario, we estimate the overall bolus injectors market to be worth USD XX billion by As expected, Cancer and related conditions are likely to account for around 45% of the total market. This will be followed by Autoimmune diseases (around 11%), blood disorders and genetic disorders (both around 8%). The rest of the market will be split amongst a variety of diseases as explained in the rest of the chapter. In terms of the market volume, we estimate around 352 million units to be sold in Figures 6.1 and 6.2 (Table 11.9 and 11.10) highlight the annual market size of the bolus injectors market. Figure 6.2 Overall Bolus Injectors Market (USD BN), Report Page 95 Cancer and Related Conditions Blood Disorders Infectious Diseases Transplantation Digestive Disorders Diabetes Skin Diseases Others Autoimmune Diseases Genetic Disorders Cardiovascular Respiratory Disorders Musculoskeletal Disorders Eye Conditions Neurologic Disorders As can be observed from the above two figures, the growth in the market is likely to be very steep after the expected launch in In the base scenario, this represents a CAGR of 138% between and a CAGR of 48% between In the conservative and optimistic scenarios, we expect the device sales to be XX million units and XX million units by 2024 respectively. The corresponding market in terms of value is likely to be USD XX billion and USD XX billion respectively. Copyright 2013 Roots Analysis Private Limited Page 6

7 6.6. BOLUS INJECTORS FOR BLOOD DISORDERS, We have identified 18 high viscous and large volume marketed and / or pipeline biologics which are being developed for blood disorders. In the base scenario, we have assumed that 9 such molecules will be ready for delivery via bolus injectors over the next ten years. Figure 6.7 and Table highlight the estimated launch timeline of these 9 molecules for delivery via bolus injectors. In terms of the volume, we forecast these 9 molecules to sell around 28 million units of bolus injectors annually by Figure 6.7 Number of Molecules in Bolus Injectors for Blood Disorders, Report Page Figure 6.8 and Table highlight the growth in the annual demand of units sold in the base scenario. In the conservative and optimistic scenarios, we expect the unit sales to be 22 million and 36 million respectively by Figure 6.8 Bolus Injectors Market for Blood Disorders (# of Devices, MM), Copyright 2013 Roots Analysis Private Limited Page 7

8 ORDER FORM REPORT TITLE Bolus Injectors Market, CUSTOMER DETAILS Name Job Title Address City ZIP Code VAT Number Company Country Phone LICENSE TYPE (TICK ONE) USD ($) EUR ( ) GBP ( ) Single-user License $1,699 1,326 1,122 Site License $3,399 2,652 2,244 Enterprise License $5,099 3,978 3,366 PAYMENT DETAILS (TICK ONE) Select preferred currency option USD ($) EUR ( ) GBP ( ) Select mode of payment Please invoice my company for I have enclosed a check, accompanied by this form, payable to Roots Analysis Private Limited PAYMENT AUTHORISATION Sign below to authorise the above payment Date NOTE Scan and this form to sales@rootsanalysis.com. The prices mentioned on this form and on the website are inclusive of all taxes. You can also buy the reports online by visiting the page For any queries, write to us at sales@rootsanalysis.com. Please note that by ordering from Roots Analysis Private Limited, you are agreeing to the Terms and Conditions at

9 DISCLAIMER This reports presents work done by analysts at Roots Analysis Private Limited. The views expressed in this report represent independent opinion of the analysts. These views are formed based on extensive business research and are published solely for guidance and information purposes. This report is not a substitute for tailored professional advice. These views shall not be misconstrued as a firm guideline for taking business decisions. We make no warranties as to the accuracy or completeness of information and opinions contained herein. This report may not be sold without the written consent of Roots Analysis. Copyright 2013 Roots Analysis Private Limited. For more information, visit